Eli Lilly

Novo seeks a cardiovascular boost
Novo seeks a cardiovascular boost
EP Vantage
Novo Nordisk
Wegovy
Eli Lilly
Mounjaro
Flag link:
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Fierce Biotech
Alzheimer's disease
patients
clinical trials
Biogen
Eisai
Eli Lilly
Flag link:
Sequoia China-Backed AI Startup Xtalpi To Partner With Pharma Giant Eli Lilly In $250 Million Novel Drug Deal
Sequoia China-Backed AI Startup Xtalpi To Partner With Pharma Giant Eli Lilly In $250 Million Novel Drug Deal
Forbes
Eli Lilly
drug discovery
China
artificial intelligence
XtalPi
Flag link:
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Biopharma Reporter
obesity
weight loss
Novo Nordisk
Eli Lilly
Pfizer
Amgen
Flag link:
Eli Lilly settles insulin suit for $13.5 million, agrees to keep price cap
Eli Lilly settles insulin suit for $13.5 million, agrees to keep price cap
Washington Post, DC
Eli Lilly
insulin
legal
drug pricing
Flag link:
Noom to offer prescriptions for weight-loss drugs
Noom to offer prescriptions for weight-loss drugs
Yahoo Finance
Noom
weightloss
Novo Nordisk
Eli Lilly
Wegovy
Ozempic
Mounjaro
Flag link:
Lilly steps up its oral obesity push
Lilly steps up its oral obesity push
EP Vantage
Eli Lilly
obesity
GLP-1 agonist
orforglipron
Flag link:
Here come the PD-1 agonists
Here come the PD-1 agonists
EP Vantage
PD-1 agonists
autoimmune disease
Eli Lilly
rheumatoid arthritis
peresolimab
Flag link:
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Drugs.com
Eli Lilly
peresolimab
rheumatoid arthritis
clinical trials
Flag link:
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
Fierce Biotech
Scribe Therapeutics
Eli Lilly
CRISPR
Prevail Therapeutics
gene therapy
biobucks
Jennifer Doudna
Flag link:
New Eli Lilly-backed neurological disease biotech Nido unveils with $109M
New Eli Lilly-backed neurological disease biotech Nido unveils with $109M
Fierce Biotech
Nido Bioscineces
Eli Lilly
neurological disorders
Kennedy's disease
precision medicine
Flag link:
Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?
Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?
Fierce Biotech
Innovent
Eli Lilly
obesity
mazdutide
clinical trials
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
BioPharma Dive
Eli Lilly
donanemab
Alzheimer's disease
physicians
Flag link:
What you need to know about pharma, PBM execs testifying on insulin prices
What you need to know about pharma, PBM execs testifying on insulin prices
Medical Marketing and Media
PBMs
insulin
diabetes
drug pricing
Sanofi
Novo Nordisk
Eli Lilly
Flag link:
Eli Lilly damages tripled to $184M in Medicaid rebate fraud case
Eli Lilly damages tripled to $184M in Medicaid rebate fraud case
Fierce Pharma
Eli Lilly
legal
fraud
Medicare
Flag link:
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Stat
side effects
Ozempic
Wegovy
Mounjaro
Novo Nordisk
Eli Lilly
obesity
Flag link:
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
BioSpace
Eli Lilly
Alzheimer's disease
donanemab
Flag link:

Pages